Literature DB >> 25572548

Anti-TNFs in axial spondyloarthritis.

Roland Kocijan1, Christian Muschitz, Jürgen Rech.   

Abstract

Since there is no evidence regarding the efficacy of conventional synthetic disease modifying anti-rheumatic drugs in the improvement of axial spondyloarthritis (SpA), anti-tumor necrosis factors (anti-TNFs) are recommended if nonsteroidal anti-inflammatory drugs fail, or in case of high disease activity. Anti-TNFs show encouraging data regarding pain reduction, improved mobility and quality of life in both ankylosing spondylitis and non-radiographic axial spondyloarthritis. However, withdrawal of anti-TNF therapy leads to relapse of disease activity in SpA. Moreover, osteoproliferation does not seem to be influenced by anti-TNFs.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25572548     DOI： 10.1007/s10354-014-0338-1

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN： 0043-5341


  21 in total

1.  Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

Authors:  Désirée van der Heijde; Alan Kivitz; Michael H Schiff; Joachim Sieper; Ben A C Dijkmans; Jürgen Braun; Maxime Dougados; John D Reveille; Robert L Wong; Hartmut Kupper; John C Davis
Journal:  Arthritis Rheum       Date:  2006-07

2.  Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab.

Authors:  X Baraliakos; J Listing; M Rudwaleit; J Brandt; J Sieper; J Braun
Journal:  Ann Rheum Dis       Date:  2005-03-18       Impact factor: 19.103

3.  Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.

Authors:  Jennifer D Gorman; Kenneth E Sack; John C Davis
Journal:  N Engl J Med       Date:  2002-05-02       Impact factor: 91.245

4.  The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general.

Authors:  M Rudwaleit; D van der Heijde; R Landewé; N Akkoc; J Brandt; C T Chou; M Dougados; F Huang; J Gu; Y Kirazli; F Van den Bosch; I Olivieri; E Roussou; S Scarpato; I J Sørensen; R Valle-Oñate; U Weber; J Wei; J Sieper
Journal:  Ann Rheum Dis       Date:  2010-11-24       Impact factor: 19.103

5.  Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis.

Authors:  Désirée van der Heijde; Robert Landewé; Xenofon Baraliakos; Harry Houben; Astrid van Tubergen; Paul Williamson; Weichun Xu; Daniel Baker; Neil Goldstein; Jürgen Braun
Journal:  Arthritis Rheum       Date:  2008-10

6.  Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial.

Authors:  In-Ho Song; Anja Weiß; Kay-Geert A Hermann; Hildrun Haibel; Christian E Althoff; Denis Poddubnyy; Joachim Listing; Ekkehard Lange; Bruce Freundlich; Martin Rudwaleit; Joachim Sieper
Journal:  Ann Rheum Dis       Date:  2012-11-21       Impact factor: 19.103

7.  2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis.

Authors:  J Braun; R van den Berg; X Baraliakos; H Boehm; R Burgos-Vargas; E Collantes-Estevez; H Dagfinrud; B Dijkmans; M Dougados; P Emery; P Geher; M Hammoudeh; R D Inman; M Jongkees; M A Khan; U Kiltz; Tk Kvien; M Leirisalo-Repo; W P Maksymowych; I Olivieri; K Pavelka; J Sieper; E Stanislawska-Biernat; D Wendling; S Ozgocmen; C van Drogen; Bj van Royen; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2011-06       Impact factor: 19.103

8.  Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.

Authors:  R Landewé; J Braun; A Deodhar; M Dougados; W P Maksymowych; P J Mease; J D Reveille; M Rudwaleit; D van der Heijde; C Stach; B Hoepken; A Fichtner; G Coteur; M de Longueville; J Sieper
Journal:  Ann Rheum Dis       Date:  2013-09-06       Impact factor: 19.103

9.  Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.

Authors:  Josef S Smolen; Jürgen Braun; Maxime Dougados; Paul Emery; Oliver Fitzgerald; Philip Helliwell; Arthur Kavanaugh; Tore K Kvien; Robert Landewé; Thomas Luger; Philip Mease; Ignazio Olivieri; John Reveille; Christopher Ritchlin; Martin Rudwaleit; Monika Schoels; Joachim Sieper; Martinus de Wit; Xenofon Baraliakos; Neil Betteridge; Ruben Burgos-Vargas; Eduardo Collantes-Estevez; Atul Deodhar; Dirk Elewaut; Laure Gossec; Merryn Jongkees; Mara Maccarone; Kurt Redlich; Filip van den Bosch; James Cheng-Chung Wei; Kevin Winthrop; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2013-06-08       Impact factor: 19.103

10.  Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial.

Authors:  D van der Heijde; M H Schiff; J Sieper; A J Kivitz; R L Wong; H Kupper; B A C Dijkmans; P J Mease; J C Davis
Journal:  Ann Rheum Dis       Date:  2008-08-13       Impact factor: 19.103
View more
  1 in total

1.  Full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China.

Authors:  Kun-Peng Li; Jing-Yu Jin; Jin-Shui Yang; Yan Li; Wei Zhao; Gui Luo; Jian Zhu; Jiang-Lin Zhang; Feng Huang
Journal:  Arch Med Sci       Date:  2018-06-01       Impact factor: 3.318
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.